Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:15358931rdf:typepubmed:Citationlld:pubmed
pubmed-article:15358931lifeskim:mentionsumls-concept:C0682313lld:lifeskim
pubmed-article:15358931lifeskim:mentionsumls-concept:C2698872lld:lifeskim
pubmed-article:15358931lifeskim:mentionsumls-concept:C1629505lld:lifeskim
pubmed-article:15358931lifeskim:mentionsumls-concept:C1548819lld:lifeskim
pubmed-article:15358931pubmed:issue5lld:pubmed
pubmed-article:15358931pubmed:dateCreated2004-9-10lld:pubmed
pubmed-article:15358931pubmed:abstractTextThis study examined the impact of three program-level factors (coercion level, type of antipsychotic prescribed, and guardian supervision) on antipsychotic medication adherence among parolees mandated to an outpatient psychiatric clinic. Overall, 70.7% of the participants tested positive for their prescribed antipsychotic. Older patients were more likely to test positive for their prescribed antipsychotic than younger patients, and African American patients (relative to all other race/ethnic groups) were less likely. With regard to program-level factors, perceived coercion was not significantly associated with medication adherence. However, being prescribed an atypical antipsychotic and having a guardian were independently associated with increased adherence, and combined, these two factors were associated with nearly a tenfold increase in the likelihood of patients testing positive for their prescribed antipsychotic agent, relative to patients who were prescribed conventional antipsychotics and were not under guardian supervision.lld:pubmed
pubmed-article:15358931pubmed:languageenglld:pubmed
pubmed-article:15358931pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15358931pubmed:citationSubsetIMlld:pubmed
pubmed-article:15358931pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15358931pubmed:statusMEDLINElld:pubmed
pubmed-article:15358931pubmed:monthOctlld:pubmed
pubmed-article:15358931pubmed:issn0306-624Xlld:pubmed
pubmed-article:15358931pubmed:authorpubmed-author:SanchezSylvia...lld:pubmed
pubmed-article:15358931pubmed:authorpubmed-author:FarabeeDavidDlld:pubmed
pubmed-article:15358931pubmed:authorpubmed-author:ShenHaikangHlld:pubmed
pubmed-article:15358931pubmed:issnTypePrintlld:pubmed
pubmed-article:15358931pubmed:volume48lld:pubmed
pubmed-article:15358931pubmed:ownerNLMlld:pubmed
pubmed-article:15358931pubmed:authorsCompleteYlld:pubmed
pubmed-article:15358931pubmed:pagination561-71lld:pubmed
pubmed-article:15358931pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:15358931pubmed:meshHeadingpubmed-meshheading:15358931...lld:pubmed
pubmed-article:15358931pubmed:meshHeadingpubmed-meshheading:15358931...lld:pubmed
pubmed-article:15358931pubmed:meshHeadingpubmed-meshheading:15358931...lld:pubmed
pubmed-article:15358931pubmed:meshHeadingpubmed-meshheading:15358931...lld:pubmed
pubmed-article:15358931pubmed:meshHeadingpubmed-meshheading:15358931...lld:pubmed
pubmed-article:15358931pubmed:meshHeadingpubmed-meshheading:15358931...lld:pubmed
pubmed-article:15358931pubmed:meshHeadingpubmed-meshheading:15358931...lld:pubmed
pubmed-article:15358931pubmed:meshHeadingpubmed-meshheading:15358931...lld:pubmed
pubmed-article:15358931pubmed:meshHeadingpubmed-meshheading:15358931...lld:pubmed
pubmed-article:15358931pubmed:meshHeadingpubmed-meshheading:15358931...lld:pubmed
pubmed-article:15358931pubmed:meshHeadingpubmed-meshheading:15358931...lld:pubmed
pubmed-article:15358931pubmed:meshHeadingpubmed-meshheading:15358931...lld:pubmed
pubmed-article:15358931pubmed:meshHeadingpubmed-meshheading:15358931...lld:pubmed
pubmed-article:15358931pubmed:meshHeadingpubmed-meshheading:15358931...lld:pubmed
pubmed-article:15358931pubmed:meshHeadingpubmed-meshheading:15358931...lld:pubmed
pubmed-article:15358931pubmed:year2004lld:pubmed
pubmed-article:15358931pubmed:articleTitleProgram-level predictors of antipsychotic medication adherence among parolees.lld:pubmed
pubmed-article:15358931pubmed:affiliationNeuropsychiatric Institute, Integrated Substance Abuse Programs, University of California Los Angeles, Los Angeles, California 90025, USA. dfarabee@ucla.edulld:pubmed
pubmed-article:15358931pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:15358931pubmed:publicationTypeResearch Support, U.S. Gov't, Non-P.H.S.lld:pubmed
pubmed-article:15358931pubmed:publicationTypeEvaluation Studieslld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15358931lld:pubmed